1. Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro.
- Author
-
Ramos JF, Leite G, Martins RCR, Rizek C, Al Sanabani SS, Rossi F, Guimarães T, Levin AS, Rocha V, and Costa SF
- Subjects
- Adolescent, Adult, Brazil, Carbapenem-Resistant Enterobacteriaceae, Carbapenems, Colistin therapeutic use, Female, Humans, Male, Meropenem therapeutic use, Microbial Sensitivity Tests, Middle Aged, Pseudomonas Infections microbiology, Pseudomonas aeruginosa genetics, Pseudomonas aeruginosa isolation & purification, Sepsis mortality, Young Adult, Anti-Bacterial Agents therapeutic use, Hematopoietic Stem Cell Transplantation, Pseudomonas Infections drug therapy, Sepsis drug therapy
- Abstract
Bloodstream infection (BSI) caused by carbapenem-resistant P. aeruginosa (CRPA) has high mortality in hematopoietic stem cell transplant (HSCT) recipients. We performed MIC, checkerboard, time-kill assay, PFGE, PCR, and whole genome sequence and described the clinical outcome through Epi Info comparing the antimicrobial combination in vitro. Mortality was higher in BSI caused by CRPA carrying the lasB virulence gene. The isolates were 97% resistant to meropenem displaying synergistic effect to 57% in combination with colistin. Seventy-three percent of the isolates harbored bla
SPM-1 and Tn4371 and belonged to ST277. The synergistic effect in vitro with meropenem with colistin appeared to be a better therapeutic option., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF